BDBM648891 8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- methyl-N-(1-(methylsulfonyl)piperidin-4- yl)pyrido[3,4-d]pyrimidin-2-amine::US20240034731, Compound 85::US20240034731, Compound 99

SMILES Cc1cc2cnc(NC3CCN(CC3)S(C)(=O)=O)nc2c(n1)N1CC2(C1)CNCC2(F)F

InChI Key InChIKey=GWFYGDVDJYLVJB-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 648891   

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK1/Cyclin B1 assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Luminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK2/Cyclin E1 assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Luminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK4/Cyclin D1 assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Chelation-En...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of the CDK6/Cyclin D3 assay is to evaluate the inhibition (% inhibition and IC50 values) in the presence of small molecule inhibitors by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK2/Cyclin El assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Luminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/5/2025
Entry Details
US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK1/Cyclin B1 assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Luminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of the CDK6/Cyclin D3 assay is to evaluate the inhibition (% inhibition and IC50 values) in the presence of small molecule inhibitors by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/5/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK2/Cyclin E1 assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Luminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK4/Cyclin D1 assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Chelation-En...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of CDK1/Cyclin Bi assay is to evaluate the inhibition (% inhibition and IC50 values) of small molecule inhibitors by using a Luminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/5/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM648891(8-(8,8-difluoro-2,6-diazaspiro[3.4]octan-2-yl)-6- ...)
Affinity DataIC50: 200nMAssay Description:The purpose of the CDK6/Cyclin D3 assay is to evaluate the inhibition (% inhibition and IC50 values) in the presence of small molecule inhibitors by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
US Patent